AlamX LLC Technology to Fight Antibiotic-Resistant Bacteria Gets U.S. Patent.Health/Medical Writers TUCSON, Ariz.--(BW HealthWire)--Dec. 19, 2000 A U.S. patent issued recently for an agent created at Southern Methodist University Southern Methodist University, at Dallas, Tex.; United Methodist; coeducational; chartered 1911. The school's facilities include laboratories for electron microscopy and stable isotopes, a museum of paleontology, and a graduate research center. in Dallas that may revitalize once-powerful drugs now sidelined by resistant bacteria. U.S. Patent No. 6,156,745 issued to Research Corporation Technologies, which formed AlamX LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control (pronounced uh-LAM-ex) this year with SMU SMU Southern Methodist University SMU Solid (Waste) Management Unit SMU Saint Mary's University (Halifax, Nova Scotia; Philippines) SMU Singapore Management University SMU Saint Mary's University of Minnesota . The two founded the company on the work of SMU chemistry professor John Buynak, who has created a variety of compounds to help fight beta-lactam-resistant bacteria. Buynak also devised new methods for commercial-scale production of these compounds. This patent protects his novel penicillin derivatives that are potent inhibitors of beta-lactamase enzymes. Beta-lactams, which include penicillins and cephalosporins Cephalosporins Definition Cephalosporins are medicines that kill bacteria or prevent their growth. Purpose Cephalosporins are used to treat infections in different parts of the body—the ears, nose, throat, lungs, sinuses, and , have been among the most useful of all antibiotics, but overuse overuse Health care The common use of a particular intervention even when the benefits of the intervention don't justify the potential harm or cost–eg, prescribing antibiotics for a probable viral URI. Cf Misuse, Underuse. and misuse have endangered their effectiveness. Some bacteria strains can now inactivate in·ac·ti·vate v. 1. To render nonfunctional. 2. To make quiescent. in·ac ti·va whole groups of beta-lactams with the enzyme beta-lactamase, allowing bacterial infection to grow unchecked. To overcome bacterial resistance to beta-lactams, current drugs combine a beta-lactam antibiotic See beta-lactam and a beta-lactamase inhibitor. Most of today's products target mainly one enzyme class. The AlamX compounds inhibit different, and in some cases multiple, classes of beta-lactamases. A two-component drug containing an AlamX inhibitor and a beta-lactam antibiotic has the potential to treat a broad spectrum of microorganisms for which no effective therapies exist. Currently, AlamX is matching several of the most promising compounds with existing antibiotics and screening these combinations against a panel of resistant microorganisms. RCT's Christopher Martin, who manages AlamX, said the market for prescription anti-infective drugs exceeded more than $20 billion in 1999. A product effective against several classes of beta-lactamases could generate annual sales in excess of $1 billion worldwide. Research Corporation Technologies (http://www.rctech.com) is an independent technology management company that commercializes technologies from universities and other research institutions worldwide. Commercialization vehicles include licensing, alliances and seed funding for promising early-stage technologies. |
|
||||||||||||||

ti·va
Printer friendly
Cite/link
Email
Feedback
Reader Opinion